Disease · MONDO_0020108
autoimmune hemolytic anemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. autoimmune hemolytic anemia. Diseases, record MONDO_0020108. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0020108
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- AHA, AIHA, Anemia, Hemolytic, Acquired Autoimmune, Anemia, Hemolytic, Autoimmune, autoimmune haemolytic anemia
- Open Targets
Drugs50
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SUTIMLIMAB | CHEMBL4297832 | Antibody | Approval | EMA Human Drugs and FDA | 3 | 0 | 0 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| FOSTAMATINIB DISODIUM | CHEMBL3989516 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PARSACLISIB | CHEMBL4297615 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| IANALUMAB | CHEMBL4594357 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OBEXELIMAB | CHEMBL4298134 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RILZABRUTINIB | CHEMBL3702854 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 50
See all 50 drugsTargets91
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| BTK | Tyrosine-protein kinase BTK | 5 | Tyrosine-protein kinase BTK inhibitor | Phase 3 | https://conductscience.org/library/genes/695 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 5 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Unknown | https://conductscience.org/library/genes/1441 | Drugs and targets |
| EPOR | Erythropoietin receptor | 3 | Erythropoietin receptor agonist | Unknown | https://conductscience.org/library/genes/2057 | Drugs and targets |
| FCGRT | IgG receptor FcRn large subunit p51 | 3 | IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| ADRM1 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| PSMA1 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5682 | Drugs and targets |
| PSMA2 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5683 | Drugs and targets |
| PSMA3 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5684 | Drugs and targets |
| PSMA4 | 26S proteasome | 2 | 26S proteasome inhibitor | Phase 2 | https://conductscience.org/library/genes/5685 | Drugs and targets |
1 to 10 of 91
See all 91 targetsTrials50
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA | Phase 3 | 90 | 2023-05-25 | Warm Antibody Autoimmune Hemolytic Anemia | FOSTAMATINIB DISODIUM | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03538041 | A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia | Phase 2 | 25 | 2022-09-22 | Autoimmune Hemolytic Anemia | PARSACLISIB | Its record names the disease | ClinicalTrials.gov |
| NCT03226678 | Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) | Phase 2 | 24 | 2024-12-12 | Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease | PEGCETACOPLAN | Its record names the disease | ClinicalTrials.gov |
| NCT05073458 | Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia | Phase 3 | 13 | 2025-01-15 | Warm Autoimmune Hemolytic Anemia (wAIHA) | PARSACLISIB | Its record names the disease | ClinicalTrials.gov |
| NCT03075878 | A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) | Phase 1/2 | 8 | 2020-05-13 | Warm Autoimmune Hemolytic Anemia | ORILANOLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04253236 | To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). | Phase 2 | 5 | 2022-07-28 | Warm Autoimmune Hemolytic Anemia | BATOCLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04657094 | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | Phase 2 | 4 | 2024-05-29 | Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia | ACALABRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT07518277 | A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia | Not applicable | 216 | Autoimmune Hemolytic Anemia (AIHA) | SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT05931718 | Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia | 200 | Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia, Autoimmune Neutropenia, Myelodysplastic Syndromes, Cold Agglutinin Disease | EPOETIN ALFA, LUSPATERCEPT | Its record names the disease | ClinicalTrials.gov | ||
| NCT05786573 | A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) | Phase 3 | 134 | Warm Autoimmune Hemolytic Anemia | OBEXELIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 50
See all 50 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Fostamatinib vs Placebo: A Hemoglobin Response by Week 24 | 21 of 45 | 16 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: Change From Baseline in Hemoglobin Level of 2 g/dL or Greater | 22 of 45 | 16 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: Use of Rescue Antibody Autoimmune Hemolytic Anemia (AIHA) Regimens Use After Week 4 | 18 of 45 | 18 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: Durable Hemoglobin Response | 16 of 45 | 12 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: deaths from any cause | 2 of 45 | 3 of 45 | 90 | NCT03764618 | Trial comparisons |
| Fostamatinib vs Placebo: serious adverse events | 15 of 45 | 17 of 45 | 90 | NCT03764618 | Trial comparisons |
| Parsaclisib 1 mg QD vs Parsaclisib 2.5 mg QD: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | 10 of 10 | 15 of 15 | 25 | NCT03538041 | Trial comparisons |
| Parsaclisib 1 mg QD vs Parsaclisib 2.5 mg QD: deaths from any cause | 0 of 10 | 1 of 15 | 25 | NCT03538041 | Trial comparisons |
| Parsaclisib 1 mg QD vs Parsaclisib 2.5 mg QD: serious adverse events | 6 of 10 | 5 of 15 | 25 | NCT03538041 | Trial comparisons |
| Parsaclisib vs Placebo: deaths from any cause | 0 of 11 | 0 of 6 | 17 | NCT05073458 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 25196783 | RESULT | 1 | PubMed |
| 42664110 | DERIVED | 1 | PubMed |
| 42263666 | DERIVED | 1 | PubMed |
| 39486046 | DERIVED | 1 | PubMed |
| 39435908 | DERIVED | 1 | PubMed |
| 38029356 | DERIVED | 1 | PubMed |
| 38013593 | DERIVED | 1 | PubMed |
| 35179251 | DERIVED | 1 | PubMed |
| 33786812 | DERIVED | 1 | PubMed |
| 22267606 | DERIVED | 1 | PubMed |
1 to 10 of 12
See all 12 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0020108
GET https://conductscience.org/api/diseases/v1/MONDO_0020108/drugs?page=2